A critical review on neurodegenerative biomarker diagnostics: where is the field heading to?

IF 3.8 2区化学 Q1 BIOCHEMICAL RESEARCH METHODS

Analytical and Bioanalytical Chemistry Pub Date : 2025-10-07 DOI:10.1007/s00216-025-06061-1

Mandana Amiri, Hosein Afshary, Abolfazl Bezaatpour, Sepideh Hatamikia, James Wei, Rabah Boukherroub, Sabine Szunerits

{"title":"A critical review on neurodegenerative biomarker diagnostics: where is the field heading to?","authors":"Mandana Amiri, Hosein Afshary, Abolfazl Bezaatpour, Sepideh Hatamikia, James Wei, Rabah Boukherroub, Sabine Szunerits","doi":"10.1007/s00216-025-06061-1","DOIUrl":null,"url":null,"abstract":"<div><p>Neurodegenerative diseases (NDD), a collection of disorders with different underlying causes and clinical presentations, are recognized as a major area of concern of our society today. The most common NDD are Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease, each one of them being characterized by the progressive degradation of nerve cells and accumulation of misfolded and aggregated proteins in the affected brain region. Diagnosing NDD is challenging, due to the heterogeneity of the disease and the overlap of symptoms. Yet, early detection and accurate diagnosis are crucial for effective NDD management. With the emergence of disease-modifying therapies for AD, monitoring disease progression and treatment success is becoming essential. The future of NND diagnostics is focusing on developing less invasive, cost-effective strategies that enable early NDD identification and detection with improved patient outcomes. The integration of biotechnology and nanotechnology is seen as crucial for advancing the analytical science aspect of NDD. The creation of these innovative tools and methodologies is on the verge of enabling new possibilities for clinical diagnostics, but is also faced with several hurdles that will be critically evaluated.</p><h3>Graphical Abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":462,"journal":{"name":"Analytical and Bioanalytical Chemistry","volume":"417 24","pages":"5435 - 5448"},"PeriodicalIF":3.8000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Analytical and Bioanalytical Chemistry","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1007/s00216-025-06061-1","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Neurodegenerative diseases (NDD), a collection of disorders with different underlying causes and clinical presentations, are recognized as a major area of concern of our society today. The most common NDD are Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease, each one of them being characterized by the progressive degradation of nerve cells and accumulation of misfolded and aggregated proteins in the affected brain region. Diagnosing NDD is challenging, due to the heterogeneity of the disease and the overlap of symptoms. Yet, early detection and accurate diagnosis are crucial for effective NDD management. With the emergence of disease-modifying therapies for AD, monitoring disease progression and treatment success is becoming essential. The future of NND diagnostics is focusing on developing less invasive, cost-effective strategies that enable early NDD identification and detection with improved patient outcomes. The integration of biotechnology and nanotechnology is seen as crucial for advancing the analytical science aspect of NDD. The creation of these innovative tools and methodologies is on the verge of enabling new possibilities for clinical diagnostics, but is also faced with several hurdles that will be critically evaluated.

Graphical Abstract

查看原文本刊更多论文

神经退行性生物标志物诊断的重要回顾：该领域将走向何方？

神经退行性疾病（NDD）是具有不同病因和临床表现的疾病的集合，是当今社会关注的一个主要领域。最常见的NDD是帕金森病（PD）、阿尔茨海默病（AD）、肌萎缩侧索硬化症（ALS）和亨廷顿病，每一种疾病的特征都是神经细胞的进行性退化以及受影响大脑区域错误折叠和聚集蛋白的积累。由于疾病的异质性和症状的重叠，诊断NDD具有挑战性。然而，早期发现和准确诊断对于有效的NDD管理至关重要。随着AD疾病修饰疗法的出现，监测疾病进展和治疗成功变得至关重要。NND诊断的未来重点是开发侵入性更小、成本效益更高的策略，从而实现NDD的早期识别和检测，并改善患者的预后。生物技术和纳米技术的结合被认为对推进NDD的分析科学方面至关重要。这些创新工具和方法的创造即将为临床诊断提供新的可能性，但也面临着一些障碍，这些障碍将被严格评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Analytical and Bioanalytical Chemistry 化学-分析化学

CiteScore

8.00

自引率

4.70%

发文量

638

审稿时长

2.1 months

期刊介绍： Analytical and Bioanalytical Chemistry’s mission is the rapid publication of excellent and high-impact research articles on fundamental and applied topics of analytical and bioanalytical measurement science. Its scope is broad, and ranges from novel measurement platforms and their characterization to multidisciplinary approaches that effectively address important scientific problems. The Editors encourage submissions presenting innovative analytical research in concept, instrumentation, methods, and/or applications, including: mass spectrometry, spectroscopy, and electroanalysis; advanced separations; analytical strategies in “-omics” and imaging, bioanalysis, and sampling; miniaturized devices, medical diagnostics, sensors; analytical characterization of nano- and biomaterials; chemometrics and advanced data analysis.